FDA Peptide Advisory Votes Could Reshape Telehealth and Compounding—But They Are Not Yet a Green Light
The debate over wellness peptides is moving out of the online “grey market” and into the formal FDA regulatory process.
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee recommended placing BPC-157, KPV, TB-500, and MOTS-C on the list of bulk drug substances that may be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. The committee reviewed both the free-base and acetate forms of the substances. It is scheduled to consider emideltide, epitalon, and Semax on July 24.
The votes could eventually create a significant opportunity for telehealth platforms, medical practices, and compounding pharmacies interested in longevity, recovery, metabolic health, and other emerging wellness services.
They do not, however, make the peptides FDA-approved. They also do not immediately authorize pharmacies or telehealth companies to begin prescribing, compounding, marketing, or shipping them nationwide.
Why the 503A Bulks List Matters
Section 503A provides a pathway through which a state-licensed pharmacy or licensed physician may compound a medication for an identified individual patient.
When a pharmacy compounds from a bulk drug substance, that substance generally must satisfy one of three conditions: it must comply with an applicable United States Pharmacopeia or National Formulary monograph, be a component of an FDA-approved drug, or appear on FDA’s 503A Bulks List. The substance must also come from an appropriately registered establishment and be accompanied by a valid certificate of analysis.
Placement on the Bulks List could therefore remove an important federal barrier to lawful compounding of certain peptides.
That is different from FDA drug approval. Compounded drugs do not go through the same premarket review as approved drugs, and FDA does not independently verify their safety, effectiveness, or quality before they are dispensed.
A favorable committee recommendation is also only one step in the process. FDA must consider the committee’s advice, complete its review, and determine how it will address the substances through regulation or enforcement policy. FDA’s own briefing materials emphasize that the agency will not make a final determination until the advisory process and its reviews are complete.
The Committee and FDA Staff Reached Different Conclusions
The votes are particularly significant because FDA staff recommended against adding the peptides considered on July 23 to the Bulks List.
FDA has identified concerns involving limited human safety information, potential immunogenicity, peptide-related impurities, and the difficulty of characterizing certain active pharmaceutical ingredients. Its existing safety materials state, for example, that it lacks sufficient information to determine whether BPC-157, KPV, MOTS-C, and TB-500 could cause harm when administered to humans through the proposed routes.
Supporters offered a different policy argument. Consumers are already purchasing peptides through overseas vendors and online sellers that label their products for research use. Allowing licensed prescribers and regulated pharmacies to serve this market, they argue, could move patients toward products with greater professional oversight, sourcing controls, testing, documentation, and traceability.
That argument may have persuaded the committee. It does not eliminate the underlying questions surrounding evidence, dosing, manufacturing quality, informed consent, adverse-event reporting, and promotional claims.
Why Telehealth Companies Are Paying Attention
Telehealth companies have already been investing in the infrastructure needed to enter the peptide and longevity markets.
Hims & Hers acquired a California-based peptide facility in 2025, describing the transaction as part of its strategy to strengthen its domestic supply chain for personalized medications. Noom announced in April 2026 that it had acquired Tailor Made Compounding, a Section 503A pharmacy operating across numerous states, as it expanded into healthy-aging and peptide-related services.
A favorable FDA decision could make those investments more commercially valuable. It could also encourage other telehealth platforms, physician groups, pharmacies, and investors to enter the market.
Vertical integration does not simplify the legal analysis, however. It can make the analysis more complicated.
A platform that owns or contracts with a medical practice, pharmacy, laboratory, marketing company, and technology provider must determine which entity is making clinical decisions, prescribing the medication, compounding it, dispensing it, communicating with the patient, collecting payment, maintaining records, and responding to safety concerns.
Each part of that arrangement can be governed by a different set of federal and state requirements.
Inclusion Would Not Permit Unrestricted Peptide Sales
Even after a substance is added to the 503A Bulks List, a pharmacy must continue to satisfy the other conditions of Section 503A.
Compounding generally must occur pursuant to a valid prescription for an identified individual patient, although limited anticipatory compounding may be permitted based on an established prescribing history. Section 503A is not intended to allow a pharmacy to operate as a conventional manufacturer or distribute standardized products without patient-specific prescriptions.
Companies must also consider:
State pharmacy and prescriber licensing requirements
Telehealth prescribing and patient-evaluation standards
Corporate-practice-of-medicine restrictions
Pharmacy ownership and management rules
Interstate dispensing and distribution limitations
Supplier qualification and certificate-of-analysis requirements
Sterility, potency, quality-control, and recordkeeping obligations
Patient disclosures and informed-consent procedures
Advertising and social-media claims
Adverse-event collection and regulatory reporting
Contracts among the platform, medical group, pharmacy, laboratory, and suppliers
The promotional issue may be especially important. A business should not describe a compounded peptide as “FDA-approved” simply because its underlying bulk substance appears on the 503A Bulks List. Claims concerning healing, recovery, weight loss, anti-aging, cognitive performance, or disease treatment must also be evaluated in light of the available evidence and applicable FDA, Federal Trade Commission, medical-board, and consumer-protection requirements.
How Lanton, Lanton & Sosa Law Can Help
Lanton, Lanton & Sosa Law assists telehealth platforms, compounding pharmacies, physicians, healthcare entrepreneurs, and investors with the legal and regulatory questions involved in developing or expanding peptide-related services.
Our attorneys can evaluate whether a proposed product and dispensing model fits within Section 503A or another regulatory pathway, review state pharmacy and medical-practice requirements, and assess corporate and contractual relationships among the telehealth platform, prescribers, pharmacies, laboratories, suppliers, and management entities.
We can also assist with pharmacy and professional licensing strategy, telehealth policies, patient disclosures, marketing review, quality and supplier agreements, adverse-event procedures, acquisition due diligence, medical- and pharmacy-board inquiries, and responses to FDA or state enforcement activity.
The peptide market may be moving toward a more regulated pathway. A single advisory committee vote does not complete that transition. Companies considering entering the market should understand how the federal compounding rules interact with state licensing, clinical practice, pharmacy operations, contracting, advertising, and patient safety before launching or expanding a program.
This article reflects developments available as of the morning of July 24, 2026. The PCAC meeting and FDA review process remain ongoing.